The story the market told about DocuSign was simple: electronic signatures were a pandemic trade, the company rode a temporary wave, and when the world reopened, the thesis expired. At roughly 78% below its all-time high closing price set on September 3, 2021, that verdict is baked into the share price with room to spare. The question today is whether it is also wrong.

A more precise read of the current business suggests it is at least incomplete. DocuSign is not the same company it was in 2021. The product has changed, the margin profile has changed, and the growth trajectory, while modest, is no longer decelerating.

The Business

DocuSign's core e-signature product remains deeply embedded in enterprise workflows globally, with more than 1.9 million customers. The strategic shift is the Intelligent Agreement Management platform, or IAM, which the company is building on top of that installed base. Rather than just capturing a signature at the end of a contract, IAM is designed to manage the entire agreement lifecycle: drafting, negotiation, execution, compliance monitoring, and renewal. AI agents now execute contract workflows end to end, with the IAM platform processing high volumes of agreements in Q2.

Deloitte estimated that poor agreement management costs businesses roughly $2 trillion in lost global economic value annually and cited more than 55 billion hours wasted globally per year. That is the market DocuSign is targeting, and it already owns the endpoint where most of those agreements close.

Why Wall Street Is Paying Attention

Q2 fiscal 2027 revenue came in at $875.7 million, up about 9% year over year, with non-GAAP EPS of $1.16 beating estimates. Non-GAAP operating margin expanded to 13.4%, up from 8.1% in the same quarter a year earlier. Free cash flow margin held around 34%. Management raised full-year revenue guidance to about $3.50 billion at the midpoint and now expects ARR growth to accelerate to 8.5%-9.0% for the fiscal year.

IAM already accounts for 15.1% of annual recurring revenue, and management guided that share toward roughly 18% to 19% exiting Q4. That transition matters because IAM contracts carry higher average selling prices and stickier renewal dynamics than standalone e-signature agreements.

What's Driving the Opportunity

The market has re-rated DocuSign partially. The stock is up roughly 62% from its year-to-date low as of early September, but it remains about 78% below its 2021 peak. Multiple analysts have raised price targets following Q2 results, including Morgan Stanley to $75 and UBS to $70, though both firms maintain cautious ratings. The gap between where the stock trades and where fundamental improvement is pointing is what creates the opportunity.

DocuSign is not alone in facing this disconnect. GitLab recently posted a 21% revenue jump and 117% net retention, yet analysts still declined to upgrade the stock — a dynamic that reveals something broader about how the Street is treating enterprise software re-ratings right now. GitLab beat estimates by 33% and Wall Street still won't buy — here's why is worth reading alongside DocuSign's setup, because the hesitation follows a similar logic in both cases.

The upcoming Q3 report in December will be the first real test of whether the IAM revenue share continues its climb toward the roughly 18% to 19% range management has guided. If it does, the growth acceleration thesis gets a third consecutive quarter of confirmation.

The stakes around that December report are real, and the risk of a muted reaction even on a beat is not hypothetical. UiPath delivered a revenue beat and its fourth straight quarter of GAAP profit in early September — and the stock fell 16% anyway. UiPath's Q2 beat and 16% post-earnings drop — what happened and what comes next illustrates how quickly a clean quarter can be overshadowed when guidance or a catalyst event disappoints, a scenario DocuSign bulls should keep in mind heading into Q3.

What Could Go Wrong

The CFO sold 45,000 shares in mid-August under a pre-arranged 10b5-1 plan. That is a meaningful transaction worth noting. Single-digit revenue growth does not make DocuSign a high-conviction compounding story in the way some bulls have framed it. Annualized revenue growth has averaged in the high single digits over the last two years, below its five-year CAGR, suggesting the deceleration from pandemic-era rates has not fully reversed.

Competition from Salesforce, Adobe, and emerging AI-native contract platforms is intensifying. If IAM adoption slows or fails to expand beyond existing customers into new enterprise segments, the growth case stalls. Consensus price targets are often close to where the stock currently trades, meaning the Street is not yet willing to price in sustained acceleration.

The Bottom Line

DocuSign is not a momentum stock, and it is not priced like one. What it offers is a free-cash-flow-generative, deeply embedded enterprise platform that is building an AI layer on top of a loyal customer base, at a valuation that reflects far more skepticism than the Q2 results justified. If IAM drives the ARR acceleration management has guided, the bears are holding a position built on a thesis that no longer matches the company's actual trajectory.